A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine

• Main Authors: Van Dyke R., Ngo-Giang-Huong N., Shapiro D., Frenkel L., Britto P., Roongpisuthipong A., Beck I., Yuthavisuthi P., Prommas S., Puthanakit T., Achalapong J., Chotivanich N., Rasri W., Cressey T., Maupin R., Mirochnick M., Jourdain G.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84555209220&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42901

Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases...